DelveInsight’s “Thyroid Eye Disease (TED) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Thyroid Eye Disease market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Thyroid Eye Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Thyroid Eye Disease (TED): An Overview
Thyroid Eye Disease (TED) is a complex orbital inflammatory disease that can be sight-threatening, debilitating, and disfiguring. TED is also known as Graves ophthalmopathy, named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goiter, rapid heartbeat, and exophthalmos.
TED affects eye muscles, eyelids, tear glands, and fatty tissues behind the eye to become inflamed. This can cause the eyes and eyelids to become red, swollen, and uncomfortable, and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes)
Thyroid Eye Disease (TED) Market Key Facts
-
According to NORD, the exact prevalence of thyroid eye disease is not known but is estimated to be 16 per 100,000 women in the general population and 2.9 per 100,000 men in the general population.
-
According to a study by Bahn et al. (2019), in approximately 40% of patients with TED, the ocular and systemic symptoms have simultaneous onset.
-
According to Karla et al. (2020), the global prevalence in patients with thyroid eye disease was 10.36% for hypothyroidism, 7.9% for euthyroidism, and 86.2% for hyperthyroidism.
-
Companies all over 7MM are persistently working towards developing novel treatment therapies to address Thyroid eye disease.
-
There are several promising drugs in the pipeline which include VRDN—001 (Viridian Therapeutics), Secukinumab (Novartis), and IMVT-1401 (Immunovant Sciences GmbH), among others. VRDN-001 is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
-
The key players are strengthening their market position through strategic mergers, agreements, and acquisitions which is expected to propel the growth of the thyroid eye disease treatment market over the forecasted period (2022-2032).
Thyroid Eye Disease (TED) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Thyroid Eye Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Thyroid Eye Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Thyroid Eye Disease (TED) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Thyroid Eye Disease (TED) Epidemiology Segmentation
Severity-Specific Cases of Thyroid Eye Disease
Diagnosed and treatable cases of Thyroid Eye Disease
Gender-specific cases of Thyroid Eye Disease
Age-specific cases of Thyroid Eye Disease
Total Prevalent cases of Thyroid Eye Disease
Thyroid Eye Disease (TED) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thyroid Eye Disease market or expected to get launched during the study period. The analysis covers the Thyroid Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Thyroid Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Thyroid Eye Disease Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market
Thyroid Eye Disease (TED) Therapeutics Analysis
Companies all over 7MM are persistently working towards the development of novel treatment therapies that can address Thyroid eye disease. There are several promising drugs in the pipeline that are expected to launch in the coming years.
Some of the key companies in the Thyroid Eye Disease (TED) Therapeutics Market include:
-
Viridian Therapeutics
-
Novartis
-
Immunovant Sciences GmbH
And many others
Thyroid Eye Disease (TED) Therapies Covered in the Report Include:
-
VRDN—001 (Viridian Therapeutics),
-
Secukinumab (Novartis)
-
IMVT-1401 (Immunovant Sciences GmbH)
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More-
https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Thyroid Eye Disease Competitive Intelligence Analysis
4. Thyroid Eye Disease Market Overview at a Glance
5. Thyroid Eye Disease Disease Background and Overview
6. Thyroid Eye Disease Patient Journey
7. Thyroid Eye Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Thyroid Eye Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Thyroid Eye Disease Unmet Needs
10. Key Endpoints of Thyroid Eye Disease Treatment
11. Thyroid Eye Disease Marketed Products
12. Thyroid Eye Disease Emerging Drugs and Latest Therapeutic Advances
13. Thyroid Eye Disease Seven Major Market Analysis
14. Attribute Analysis
15. Thyroid Eye Disease Market Outlook (In US, EU5, and Japan)
16. Thyroid Eye Disease Access and Reimbursement Overview
17. KOL Views on the Thyroid Eye Disease Market
18. Thyroid Eye Disease Market Drivers
19. Thyroid Eye Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Hypertrophic Cardiomyopathy (HCM) Market
“Hypertrophic Cardiomyopathy (HCM) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/